Enveric Biosciences (ENVB)
(Delayed Data from NSDQ)
$0.46 USD
-0.02 (-3.18%)
Updated Sep 23, 2024 11:06 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Enveric Biosciences, Inc. [ENVB]
Reports for Purchase
Showing records 1 - 9 ( 9 total )
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Announces Strategic Partnerships with Potential Milestones Up to $410 Million, While Advancing EB-003 Towards Clinical Trial
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Enveric Biosciences, Inc.
Industry: Technology Services
FY 2023 Financial Results Highlight Strategic Advances in Product Development, Business Expansion, and Strengthened Financial Position
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Next-Generation Neuroplastogens for Mental Health Disorders; Initiating With a Buy and $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Progressing Promising Neuroplastogen Pipeline with Significant Developments
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Multiple Pipeline Developments with Portfolio Expansion
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Sequential Advancements in Intellectual Property Strengthen Enveric Biosciences'' Position in Neuroplastogenic Therapeutics
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Sequential Advancements in Intellectual Property Strengthen Enveric Biosciences'' Position in Neuroplastogenic Therapeutics
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: Enveric Biosciences, Inc.
Industry: Technology Services
Company: Enveric Biosciences, Inc.
Industry: Technology Services
|